REG - Target H'care REIT - Appointment of Joint Broker

Target Healthcare ReitAnnouncement

05/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250305:nRSE3455Za&default-theme=true

RNS Number : 3455Z  Target Healthcare REIT PLC  05 March 2025

5 March
2025

Target Healthcare REIT plc and its subsidiaries

("Target Healthcare" or "the Group")

Appointment of Joint Broker

 

Target Healthcare (LSE: THRL), the UK listed specialist investor in modern,
purpose-built care homes, is pleased to announce the appointment of Panmure
Liberum Limited ("Panmure Liberum") as joint broker, to work alongside Stifel
Nicolaus Europe Limited, the Group's existing corporate broker, with immediate
effect.

 

LEI: 213800RXPY9WULUSBC04

 

For further information, please contact:

 Target Fund Managers Limited    Tel: 01786 845 912
   Kenneth MacKenzie

   Gordon Bland

 Stifel Nicolaus Europe Limited  Tel: 020 7710 7600
   Mark Young

   Rajpal Padam

   Catriona Neville

 Panmure Liberum Limited         Tel: 020 3100 2000
   Jamie Richards

   David Watkins

   Nikhil Varghese

   Dougie McLeod

 FTI Consulting                  Tel: 020 3727 1000
   Dido Laurimore                TargetHealthcare@fticonsulting.com (mailto:TargetHealthcare@fticonsulting.com)

   Richard Gotla

Notes to editors:

UK listed Target Healthcare REIT plc (THRL) is an externally managed Real
Estate Investment Trust which provides shareholders with an attractive level
of income, together with the potential for capital and income growth, from
investing in a diversified portfolio of modern, purpose-built care homes.

The Group's portfolio at 31 December 2024 comprised 94 assets let to 34
tenants with a total value of £924.7 million.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPDZLFBEXLFBBD